"Method Of Extracorporeal Photopheresis For Immune-Related Adverse Events" in Patent Application Approval Process (USPTO 20230165961).

"As used herein the term "blood sample" comprises all kinds of blood-derived samples, including blood-cell samples such as MNC samples that are generated from blood. "Preferably, the immunoregulatory NK cells for use in such a treatment or prevention have been generated by adding a photosensitizing agent to a sample derived from a blood sample of a human subject and subjecting the sample to irradiation. It surprisingly could be shown that administration of such a sample or cells comprised in such a sample that underwent the method of the invention to a subject that has received a checkpoint-inhibitor therapy is effective in preventing the occurrence of irAE and even in the treatment of irAE that is already established in the subject. "In preferred embodiments, the blood sample used for generating the immunoregulatory NK cells of the invention is from a subject that has received a checkpoint-inhibitor therapy and is suspected of developing or has developed symptoms of immune-related adverse events (irAE). [Extracted from the article]